Gilead holds 25.84% of Galapagos shares
January 09 2020 - 4:01PM
Gilead holds 25.84% of Galapagos shares
Mechelen, Belgium; 9 January 2020; 22.01 CET;
regulated information – Galapagos NV (Euronext & NASDAQ: GLPG)
received a transparency notification from Gilead Sciences,
Inc.
Pursuant to Belgian transparency legislation1,
Galapagos received a transparency notification on 7 January 2020
from Gilead Sciences, Inc., who notified that certain changes
occurred in the chain of intermediary companies through which
Gilead holds its shares in Galapagos, more specifically that (i) on
27 December 2019, Gilead Biopharmaceutics US, LLC, a direct
subsidiary of Gilead Sciences, Inc., acquired control over Gilead
Biopharmaceutics Ireland UC, and that (ii) on 28 December 2019,
Gilead Sciences Ireland UC, a direct subsidiary of Gilead
Biopharmaceutics Ireland UC, acquired control over Gilead
Therapeutics A1 Unlimited Company, an indirect subsidiary of Gilead
Sciences, Inc., who holds 16,707,477 of Galapagos' voting rights,
consisting of 16,707,477 shares. The 16,707,477 shares represent an
increase of 500,000 share since Gilead’s last transparency notice
on 11 November 2019, now amounting to 25.84% of Galapagos'
currently outstanding 64,666,802 shares. Gilead Sciences Ireland UC
thus crossed above the 25% threshold of Galapagos' voting rights by
acquisition of control over Gilead Therapeutics A1 Unlimited
Company on 28 December 2019.
The full transparency notification is available
on the Galapagos website.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG)
discovers and develops small molecule medicines with novel modes of
action, three of which show promising patient results and are
currently in late-stage development in multiple diseases. The
Company's pipeline comprises Phase 3 through to discovery programs
in inflammation, fibrosis, osteoarthritis and other indications.
Galapagos' ambition is to become a leading global biopharmaceutical
company focused on the discovery, development and commercialization
of innovative medicines. More information at www.glpg.com.
Galapagos
Contacts |
|
Investors: |
Media: |
Elizabeth
Goodwin |
Carmen
Vroonen |
VP IR |
Senior Director
Communications |
+1 781 460
1784 |
+32 473 824
874 |
|
|
Sofie Van
Gijsel |
Evelyn Fox |
Director
IR |
Director
Communications |
+32 485 19 14
15 |
+31 6 53 591
999 |
ir@glpg.com |
communications@glpg.com |
1 Belgian Act of 2 May 2007 on the disclosure of
major shareholdings in issuers whose shares are admitted to trading
on a regulated market and regarding miscellaneous provisions.
Galapagos (EU:GLPG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Sep 2023 to Sep 2024